Amedisys (AMED) Tops Q3 EPS by $0.16

Amedisys (NASDAQ: AMED) reported Q3 EPS of $1.53, $0.16 better than the analyst estimate of $1.37. Revenue for the quarter came in at $553.5 versus the consensus estimate of $568.37 million.

GUIDANCE:

Amedisys sees FY2021 EPS of $5.88-$5.93, versus the consensus of $6.08. Amedisys sees FY2021 revenue of $2.2-2.205 billion, versus the consensus of $2.25 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c